🇺🇸 Levothyroxine Sodium Tablets in United States

948 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 153 reports (16.14%)
  2. Drug Ineffective — 134 reports (14.14%)
  3. Alopecia — 111 reports (11.71%)
  4. Headache — 88 reports (9.28%)
  5. Diarrhoea — 85 reports (8.97%)
  6. Feeling Abnormal — 83 reports (8.76%)
  7. Dizziness — 79 reports (8.33%)
  8. Pruritus — 74 reports (7.81%)
  9. Palpitations — 71 reports (7.49%)
  10. Insomnia — 70 reports (7.38%)

Source database →

Levothyroxine Sodium Tablets in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Levothyroxine Sodium Tablets approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Levothyroxine Sodium Tablets in United States?

Second Affiliated Hospital, School of Medicine, Zhejiang University is the originator. The local marketing authorisation holder may differ — check the official source linked above.